Evidence map›Paper›PMID 34618873›Full record

ArticlePLoS pathogens2021

Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.

Pengcheng Zhou, Jiali Chen, Jing He, Ting Zheng, Joseph Yunis, Victor Makota, Yannick O Alexandre, Fang Gong, Xia Zhang, Wuxiang Xie and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Low-dose interleukin-2 therapy in systemic lupus erythematosus.Rheumatology and immunology research · 2023
    Review
  9. Lessons from Animal Models in Sjögren's Syndrome.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Enriched CXCR3The Journal of infection · 2023
    Article
  12. Article
  13. Review
  14. Low-dose IL-2 reduces IL-21Nature communications · 2022
    Article
  15. Review
  16. Protein vaccine NVX-CoV2373 elicits functional T cell immunity.The Journal of clinical investigation · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 2 countries.

Pengcheng ZhouDepartment of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.ORCID 0000-0002-7736-2902
Jiali ChenDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Jing HeDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Ting ZhengLaboratory of Immunology for Environment and Health, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Joseph YunisThe University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.ORCID 0000-0002-0272-0605
Victor MakotaDepartment of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Yannick O AlexandreDepartment of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Fang GongDepartment of Laboratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China.ORCID 0000-0002-8035-7645
Xia ZhangDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Wuxiang XiePeking University Clinical Research Institute, Peking University Health Science Center, Beijing, China.ORCID 0000-0001-7527-1022
Yuhui LiDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Miao ShaoDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Yanshan ZhuSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
Jane E SinclairSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
Miao MiaoDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Yaping ChenMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID 0000-0002-1940-0966
Kirsty R ShortSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
Scott N MuellerDepartment of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-3838-3989
Xiaolin SunDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Di YuDepartment of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Zhanguo LiDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.ORCID 0000-0002-2590-6242
Peking University · CNAustralian National University · AUThe University of Queensland · AUThe University of Melbourne · AUJiangnan University · CNMonash University · AUQilu University of Technology · CNTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its influence on infection, we retrospectively studied 665 patients with systemic lupus erythematosus (SLE) including about one third receiving Ld-IL2 therapy, where Ld-IL2 therapy was found beneficial in reducing the incidence of infections. In line with this clinical observation, IL-2 treatment accelerated viral clearance in mice infected with influenza A virus or lymphocytic choriomeningitis virus (LCMV). Noticeably, despite enhancing anti-viral immunity in LCMV infection, IL-2 treatment exacerbated CD8+ T cell-mediated immunopathology. In summary, Ld-IL2 therapy reduced the risk of infections in SLE patients and enhanced the control of viral infection, but caution should be taken to avoid potential CD8+ T cell-mediated immunopathology.

Indexed as

AnimalsCD8-Positive T-LymphocytesCohort StudiesFemaleHumansImmunocompromised HostImmunosuppressive AgentsInterleukin-2Lupus Erythematosus, SystemicMaleMiceMice, Inbred C57BLOpportunistic InfectionsRetrospective StudiesImmunosuppressive AgentsInterleukin-2

Identifiers

PMID34618873
PMCPMC8525737
OpenAlexW3204847426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.